Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Technical University of Munich
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02307396CT.gov Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients | — | Completed | — | — | — |
NCT02199743CT.gov Lurasidone Effects on Tissue Glutamate in Schizophrenia | — | Completed | — | — | — |
NCT00480571CT.gov Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizoaffective Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Perphenazine (this asset) | Technical University of Munich | Approved | BB · 68 |
| Paliperidone | Luye Pharma Group Ltd. | P4 | BBB |
| Risperidone | Lyndra Inc. | P4 | BBB |
| Olanzapine | The Royal Ottawa Mental Health Centre | P4 | BBB |
| Dexmedetomidine | BioXcel Therapeutics Inc | P4 | BBB |
| Lurasidone | University of Texas Southwestern Medical Center | P4 | BBB |
| Raloxifene | Iris Sommer | P4 | BBB |
| Ziprasidone | Centre for Addiction and Mental Health | P4 | BBB |
| Quetiapine | Otsuka Pharmaceutical Development & Commercialization, Inc. | P4 | BBB |
+42 more in the Schizoaffective Disorder cohort
Other indications for Perphenazine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Psychotic Disorder | — | P4 | BB · 70 |
| Schizophrenia | — | P4 | BB · 68 |
| Vascular Dementia | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Perphenazine in Schizoaffective Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/perphenazine-schizoaffective-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →